Health Economic Benefits and Quality of Life During Improved Glycemic Control in Patients With Type 2 Diabetes Mellitus: A Randomized, Controlled, Double-Blind Trial

CONTEXT.— Although the long-term health benefits of good glycemic control in patients with diabetes are well documented, shorter-term quality of life (QOL) and economic savings generally have been reported to be minimal or absent. OBJECTIVE.— To examine short-term outcomes of glycemic control in typ...

Full description

Saved in:
Bibliographic Details
Published in:JAMA : the journal of the American Medical Association 1998-11, Vol.280 (17), p.1490-1496
Main Authors: Testa, Marcia A, Simonson, Donald C
Format: Article
Language:English
Subjects:
Absenteeism
Adult
Aged
Aged, 80 and over
Biological and medical sciences
Blood Glucose - metabolism
Cost of Illness
Diabetes
Diabetes Mellitus, Type 2 - economics
Diabetes Mellitus, Type 2 - therapy
Diabetes. Impaired glucose tolerance
Diet
Double-Blind Method
Drug therapy
Endocrine pancreas. Apud cells (diseases)
Endocrinopathies
Female
Glipizide - administration & dosage
Glipizide - therapeutic use
Humans
Hypoglycemic Agents - administration & dosage
Hypoglycemic Agents - therapeutic use
Male
Management. Various non-drug treatments. Langerhans islet grafts
Medical sciences
Middle Aged
Quality of Life
Self-Assessment
Surveys and Questionnaires
United States
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:CONTEXT.— Although the long-term health benefits of good glycemic control in patients with diabetes are well documented, shorter-term quality of life (QOL) and economic savings generally have been reported to be minimal or absent. OBJECTIVE.— To examine short-term outcomes of glycemic control in type 2 diabetes mellitus (DM). DESIGN.— Double-blind, randomized, placebo-controlled, parallel trial. SETTING.— Sixty-two sites in the United States. PARTICIPANTS.— A total of 569 male and female volunteers with type 2 DM. INTERVENTION.— After a 3-week, single-blind placebo-washout period, participants were randomized to diet and titration with either 5 to 20 mg of glipizide gastrointestinal therapeutic system (GITS) (n=377) or placebo (n=192) for 12 weeks. MAIN OUTCOME MEASURES.— Change from baseline in glucose and hemoglobin A1c (HbA1c) levels and symptom distress, QOL, and health economic indicators by questionnaires and diaries. RESULTS.— After 12 weeks, mean (±SE) HbA1c and fasting blood glucose levels decreased with active therapy (glipizide GITS) vs placebo (7.5%±0.1% vs 9.3%±0.1% and 7.0±0.1 mmol/L [126±2 mg/dL] vs 9.3±0.2 mmol/L [168±4 mg/dL], respectively; P
ISSN:0098-7484
1538-3598
DOI:10.1001/jama.280.17.1490